NanoViricides says pre-IND meeting with FDA for FluCide “successful”

Via Scoop.itVirology News

NanoViricides (OTC:NNVC) said Monday that the U.S. health regulator gave a “good roadmap” toward an investigational new drug (IND) application for the company’s lead candidate FluCide, at a recent pre-IND meeting.
The previously announced meeting was held with the U.S. Food and Drug Administration on March 29, as scheduled.
NanoViricides said the meeting focused on FluCide, designated as NV-INF-1, the company’s anti influenza drug.


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: